Thyroid eye disease (TED) is an autoimmune condition in which cells target tissues behind the eyes. It causes inflammation, swelling, eye redness and irritation, lid retraction, bulging of the eyes, and double vision. Knowing the signs is essential for management and care. Herein we outline the list as well as how to treat.
The disease typically unfolds in two phases. An “active” inflammatory phase brings progressive symptoms over months, followed by an “inactive” or fibrotic phase in which inflammation quiets but residual changes may persist. Smoking is the single most important modifiable risk factor; smokers are more likely to develop TED, experience more severe disease, and respond less well to treatment. Women are affected more often overall, but men tend to present with more severe findings when TED occurs. Restoring and maintaining a euthyroid state is a cornerstone of care because swings in thyroid hormone can worsen ocular inflammation. (NEI)
The symptom list includes bulging, eye irritation, dry eyes, teary eyes, swollen eyes, light sensitivity, eye pain, difficulty moving eyes, and double vision. There may be gritty, dry, light-sensitive eyes and tearing to pressure pain behind the eyes and diplopia from enlarged, stiff eye muscles. Family or friends may notice widening of the lid opening or forward prominence of the eyes in photos. Warning signs that demand urgent attention include rapidly decreasing vision, diminished color perception, pain with eye movement, or progressive blurring that suggests compressive optic neuropathy or corneal exposure. Early evaluation helps distinguish active inflammation from long-standing changes and guides timely therapy.
Diagnosis rests on clinical examination supported by thyroid blood tests and orbital imaging when needed. Eye doctors assess lid position, degree of proptosis, motility restriction, corneal health, and optic nerve function, often tracking disease activity with standardized scores. CT or MRI can show enlargement of extraocular muscles and inflamed orbital fat, helping confirm TED and rule out mimics. Because TED can precede or follow changes in thyroid status, endocrinologic testing and follow-up run in parallel with ophthalmic care. (Cleveland Clinic)
Initial management focuses on protecting the ocular surface, calming inflammation, and addressing systemic risks. Frequent preservative-free lubricants, nighttime ointment, head-of-bed elevation, and temporary prisms for double vision can improve comfort and function. Strict smoking cessation is strongly advised. Achieving stable, normal thyroid hormone levels is prioritized, and in selected patients with mild, active disease—especially in selenium-deficient regions—short-term selenium supplementation may be considered as part of a comprehensive plan. Care is individualized based on activity, severity, and patient priorities.
For moderate-to-severe active TED, anti-inflammatory and immunomodulating treatments come to the forefront. High-dose intravenous corticosteroids are commonly used when inflammation is brisk, sometimes alongside orbital radiation to reduce swelling of the eye muscles. In 2020, the U.S. Food and Drug Administration approved teprotumumab, the first medication specifically indicated for TED; this monoclonal antibody targets the insulin-like growth factor-1 receptor pathway implicated in orbital inflammation and has been shown to reduce proptosis and diplopia in many patients with active disease. Decisions about systemic therapy weigh benefits against potential adverse effects and are made jointly by ophthalmology and endocrinology teams. (NIH)
Surgery plays different roles depending on timing and urgency. When vision is threatened by optic nerve compression or extreme corneal exposure, urgent orbital decompression can create space for the swollen tissues and relieve pressure. In the inactive phase, staged rehabilitation is common: decompression to set eye position, strabismus surgery to align the eyes and reduce double vision, and eyelid surgery to correct lid retraction or exposure. These procedures are typically delayed until inflammation has quieted to avoid chasing shifting anatomy and to maximize stability of results.
Prognosis has improved substantially with earlier recognition and modern therapies. Many people experience stabilization and meaningful improvement as the active phase resolves, though some may have persistent diplopia or cosmetic changes that can be addressed surgically. Lifelong follow-up is prudent because thyroid status can change and eye symptoms can fluctuate, particularly with smoking or uncontrolled thyroid disease. A team approach—combining patient education, meticulous ocular surface care, smoking cessation, endocrine stability, and timely use of medical or surgical treatments—offers the best chance to protect vision and quality of life.
Clarity-Spot is for informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on Clarity-Spot.